-
1
-
-
78650561670
-
Rheumatology
-
In: MacGregor AJ, Silman AJ, editors, 4th ed. Spain: Mosby
-
Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. In: MacGregor AJ, Silman AJ, editors. Classification and epidemiology. 4th ed. Spain: Mosby; 2008. p.755-62.
-
(2008)
Classification and Epidemiology
, pp. 755-762
-
-
Hochberg, M.C.1
Silman, A.J.2
Smolen, J.S.3
Weinblatt, M.E.4
Weisman, M.H.5
-
2
-
-
34249720998
-
Cytokines in the pathogenesis of rheumatoid arthritis
-
McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
-
(2007)
Nat Rev Immunol
, vol.7
, pp. 429-442
-
-
McInnes, I.B.1
Schett, G.2
-
3
-
-
34247130945
-
Update on cytokines in rheumatoid arthritis
-
Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:296-301.
-
(2007)
Curr Opin Rheumatol
, vol.19
, pp. 296-301
-
-
Brennan, F.1
Beech, J.2
-
4
-
-
34247127472
-
Macrophages and their products in rheumatoid arthritis
-
Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:289-295.
-
(2007)
Curr Opin Rheumatol
, vol.19
, pp. 289-295
-
-
Szekanecz, Z.1
Koch, A.E.2
-
5
-
-
33745612984
-
Synovial fibroblasts: Key players in rheumatoid arthritis
-
Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006;45:669-675.
-
(2006)
Rheumatology
, vol.45
, pp. 669-675
-
-
Huber, L.C.1
Distler, O.2
Tarner, I.3
Gay, R.E.4
Gay, S.5
Pap, T.6
-
7
-
-
0027518860
-
Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity
-
Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4.
-
(1993)
Ann Rheum Dis
, vol.52
, pp. 232-234
-
-
Madhok, R.1
Crilly, A.2
Watson, J.3
Capell, H.A.4
-
8
-
-
38049187988
-
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis
-
Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, Nielsen L, et al. Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 2008;13:59-78.
-
(2008)
Biomarkers
, vol.13
, pp. 59-78
-
-
Knudsen, L.S.1
Christensen, I.J.2
Lottenburger, T.3
Svendsen, M.N.4
Nielsen, H.J.5
Nielsen, L.6
-
9
-
-
40749114497
-
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial
-
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-997.
-
(2008)
Lancet
, vol.371
, pp. 987-997
-
-
Smolen, J.S.1
Beaulieu, A.2
Rubbert-Roth, A.3
Ramos-Remus, C.4
Rovensky, J.5
Alecock, E.6
-
10
-
-
54949150604
-
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
-
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-2980.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 2968-2980
-
-
Genovese, M.C.1
McKay, J.D.2
Nasonov, E.L.3
Mysler, E.F.4
da Silva, N.A.5
Alecock, E.6
-
11
-
-
52149099504
-
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial
-
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-1523.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1516-1523
-
-
Emery, P.1
Keystone, E.2
Tony, H.P.3
Cantagrel, A.4
van Vollenhoven, R.5
Sanchez, A.6
-
13
-
-
0038667615
-
The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover
-
Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003;48:1177-1189.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 1177-1189
-
-
Wong, P.K.1
Campbell, I.K.2
Egan, P.J.3
Ernst, M.4
Wicks, I.P.5
-
14
-
-
0030903094
-
The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis
-
Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997;40:1096-1105.
-
(1997)
Arthritis Rheum
, vol.40
, pp. 1096-1105
-
-
Okamoto, H.1
Yamamura, M.2
Morita, Y.3
Harada, S.4
Makino, H.5
Ota, Z.6
-
15
-
-
0031744306
-
Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
-
Robak T, Gladalska A, Stepień H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998;7:347-353.
-
(1998)
Mediators Inflamm
, vol.7
, pp. 347-353
-
-
Robak, T.1
Gladalska, A.2
Stepień, H.3
Robak, E.4
-
16
-
-
0027241614
-
Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides
-
Waring PM, Carroll GJ, Kandiah DA, Buirski G, Metcalf D. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1993;36:911-5.
-
(1993)
Arthritis Rheum
, vol.36
, pp. 911-915
-
-
Waring, P.M.1
Carroll, G.J.2
Kandiah, D.A.3
Buirski, G.4
Metcalf, D.5
-
17
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 315-324
-
-
Arnett, F.C.1
Edworthy, S.M.2
Bloch, D.A.3
McShane, D.J.4
Fries, J.F.5
Cooper, N.S.6
-
18
-
-
0028815803
-
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
-
Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
-
(1995)
Arthritis Rheum
, vol.38
, pp. 44-48
-
-
Prevoo, M.L.1
van 't Hof, M.A.2
Kuper, H.H.3
van Leeuwen, M.A.4
van de Putte, L.B.5
van Riel, P.L.6
-
19
-
-
41649120761
-
Activity assessments in rheumatoid arthritis
-
Smolen JS, Aletaha D. Activity assessments in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:306-313.
-
(2008)
Curr Opin Rheumatol
, vol.20
, pp. 306-313
-
-
Smolen, J.S.1
Aletaha, D.2
-
20
-
-
33750446619
-
Monitoring disease activity of rheumatoid arthritis in clinical practice: Contributions from clinical trials
-
Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nat Clin Pract Rheumatol 2006;2:611-8.
-
(2006)
Nat Clin Pract Rheumatol
, vol.2
, pp. 611-618
-
-
Zatarain, E.1
Strand, V.2
-
21
-
-
0031826987
-
Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis
-
Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998;41: 1388-1397.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1388-1397
-
-
Hermann, J.A.1
Hall, M.A.2
Maini, R.N.3
Feldmann, M.4
Brennan, F.M.5
-
22
-
-
0031679923
-
An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis
-
Walmsley M, Butler DM, Marinova-Mutafchieva L, Feldmann M. An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology 1998;95:31-7.
-
(1998)
Immunology
, vol.95
, pp. 31-37
-
-
Walmsley, M.1
Butler, D.M.2
Marinova-Mutafchieva, L.3
Feldmann, M.4
-
23
-
-
17844403234
-
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
-
Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, et al. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 2001;3:247-252.
-
(2001)
Arthritis Res
, vol.3
, pp. 247-252
-
-
Moreland, L.1
Gugliotti, R.2
King, K.3
Chase, W.4
Weisman, M.5
Greco, T.6
-
24
-
-
0027241173
-
Leukaemia inhibitory factor stimulates proteoglycan resorption in porcine articular cartilage
-
Carroll GJ, Bell MC. Leukaemia inhibitory factor stimulates proteoglycan resorption in porcine articular cartilage. Rheumatol Int 1993;13:5-8.
-
(1993)
Rheumatol Int
, vol.13
, pp. 5-8
-
-
Carroll, G.J.1
Bell, M.C.2
-
25
-
-
0027298229
-
Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha
-
Campbell IK, Waring P, Novak U, Hamilton JA. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum 1993;36:790-4.
-
(1993)
Arthritis Rheum
, vol.36
, pp. 790-794
-
-
Campbell, I.K.1
Waring, P.2
Novak, U.3
Hamilton, J.A.4
-
26
-
-
0344193128
-
Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs
-
Straub RH, Müller-Ladner U, Lichtinger T, Schölmerich J, Menninger H, Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br J Rheumatol 1997;36:1298-1303.
-
(1997)
Br J Rheumatol
, vol.36
, pp. 1298-1303
-
-
Straub, R.H.1
Müller-Ladner, U.2
Lichtinger, T.3
Schölmerich, J.4
Menninger, H.5
Lang, B.6
-
27
-
-
0028328436
-
Impaired immune and acute-phase responses in interleukin-6-deficient mice
-
Kopf M, Baumann H, Freer G, Feudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-342.
-
(1994)
Nature
, vol.368
, pp. 339-342
-
-
Kopf, M.1
Baumann, H.2
Freer, G.3
Feudenberg, M.4
Lamers, M.5
Kishimoto, T.6
-
28
-
-
0033503152
-
Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice
-
Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999;42:1635-1643.
-
(1999)
Arthritis Rheum
, vol.42
, pp. 1635-1643
-
-
Sasai, M.1
Saeki, Y.2
Ohshima, S.3
Nishioka, K.4
Mima, T.5
Tanaka, T.6
-
29
-
-
0032518415
-
IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses
-
Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311-320.
-
(1998)
J Clin Invest
, vol.101
, pp. 311-320
-
-
Xing, Z.1
Gauldie, J.2
Cox, G.3
Baumann, H.4
Jordana, M.5
Lei, X.F.6
-
30
-
-
35748978843
-
Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis
-
Cronstein BN. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65 Suppl 1:S11-S15.
-
(2007)
Bull NYU Hosp Jt Dis
, vol.65
, Issue.SUPPL 1
-
-
Cronstein, B.N.1
-
31
-
-
0026537559
-
Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11
-
Yin TG, Schendel P, Yang YC. Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med 1992;175:211-6.
-
(1992)
J Exp Med
, vol.175
, pp. 211-216
-
-
Yin, T.G.1
Schendel, P.2
Yang, Y.C.3
-
32
-
-
0030587817
-
Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production
-
Trepicchio WL, Bozza M, Pedneault G, Dorner AJ. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996;157:3627-3634.
-
(1996)
J Immunol
, vol.157
, pp. 3627-3634
-
-
Trepicchio, W.L.1
Bozza, M.2
Pedneault, G.3
Dorner, A.J.4
|